Rockefeller University
Clinical trials sponsored by Rockefeller University, explained in plain language.
-
Can two antibodies plus an immune booster keep HIV in check? new study explores a pill-free option.
Disease control CompletedThis study tested whether a single infusion of two long-acting antibodies (3BNC117-LS and 10-1074-LS) plus repeated doses of an immune-stimulating drug (N-803) can safely control HIV in people who temporarily stop their daily antiretroviral therapy. 28 adults with well-controlled…
Phase: PHASE1 • Sponsor: Rockefeller University • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
Could antibody infusions replace daily HIV pills?
Disease control CompletedThis study tested whether infusions of two lab-made antibodies (3BNC117 and 10-1074) can safely control HIV in people who temporarily stop their daily antiretroviral therapy (ART). Twenty-six adults with well-controlled HIV received seven antibody infusions and were monitored for…
Phase: PHASE1 • Sponsor: Rockefeller University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Compassion training eases racism stress in small pilot study
Symptom relief CompletedThis study tested a 10-week compassion-based training program to help African Americans deal with stress caused by racism. 22 adults took part, learning mindfulness and self-compassion techniques. The goal was to see if the program was practical and helpful for reducing psycholog…
Phase: NA • Sponsor: Rockefeller University • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC
-
Antibiotics may temporarily alter gut nerves, small study suggests
Knowledge-focused CompletedThis study looked at how a single course of antibiotics affects nerve and support cells in the lower gut of 10 healthy adults. Researchers took colon tissue samples before and after antibiotic treatment to count changes in these cells. The goal was to understand if antibiotics ca…
Phase: PHASE4 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated May 26, 2026 11:31 UTC
-
New HIV antibody passes early safety check in 43 volunteers
Knowledge-focused CompletedThis early-stage study tested a single dose of a lab-made antibody called 3BNC117-LS in 43 adults, both with and without HIV. The main goals were to see if it is safe and how long it remains in the bloodstream. No treatment or prevention benefit was measured; the study focused on…
Phase: PHASE1 • Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated May 26, 2026 11:28 UTC